ENDOMETRIAL CANCER

The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.

According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.

According to The Cancer Genome Atlas and the ProMisE algorithm, there are 4 molecular subtypes of endometrial cancer, including POLE, dMMR, p53 abnormal, and no specific molecular profile.

The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.

Patients with endometrial cancer were more likely to have cardiovascular disease before and after their cancer diagnosis compared with patients without cancer.

Centering discussion on safety and efficacy data from the GARNET trial, Bhavana Pothuri, MD, reflects on the role of dostarlimab therapy in patients with recurrent metastatic endometrial cancer.

Comprehensive insight to the systemic treatment armamentarium available to patients with metastatic EC.

Expert perspective on the presentation of endometrial cancer, followed by advice on providing optimal workup and diagnosis.

Expert oncologist Bhavana Pothuri, MD, reviews the diagnosis and treatment of a 64-year-old woman who presents and recurs with mismatch repair-deficient (dMMR) endometrial cancer (EC).

Robust and durable antitumor activity continues to be shown with pembrolizumab in patients with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.

According to patient-reported outcomes for those with endometrial cancer, the combination of lenvatinib plus pembrolizumab was favored over treatment of physician's choice.

In the SIENDO clinical trials, selinexor show progression-free survival benefit in patients with select endometrial cancer subtypes.

Patients with either breast cancer, endometrial cancer, or ovarian cancer have started treatment with XMT-1660 in a phase 1 clinical trial.

The FDA has approved a label expansion for the VENTANA MMR RxDx panel to identify patients with dMMR solid tumors and pMMR endometrial cancer who are eligible for treatment with pembrolizumab.

Improvement in progression-free survival and safety demonstrated with the addition of vistusertib to anastrozole vs anastrozole alone in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

David Barrington, MD, discusses his advice on molecular testing for patients with stage 1B, grade 3 endometrial cancer.

An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.

David Barrington, MD, discusses adjuvant treatments that are currently available for patients with stage 1B, grade 3 endometrial cancer.

An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.

The field of gynecologic cancer continues to leverage the role of immunotherapy and novel treatments to treat patients who have new diagnoses or who have recurrent disease.

Bhavana Pothuri, MD, discusses ongoing and potential studies of copy-number low and high subgroups of patients with endometrial cancer.

Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Selinexor shows statistically significant improvement in progression-free survival in patients with endometrial cancer.

Closing out his discussion on advanced endometrial carcinoma, Michael Birrer, MD, PhD, shares his hope for future treatment advances.

Expert perspectives on Study 309/KEYNOTE-775, which combined pembrolizumab with lenvatinib in patients with advanced endometrial carcinoma.

Insight on the optimal sequencing of therapy in patients with advanced endometrial cancer based on MMR and MSI status.

Michael Birrer, MD, PhD, considers the role of pembrolizumab in advanced endometrial cancer given results from KEYNOTE-158.